Baird on Benitec BioPharma (BNTC): 'Incrementally positive on data update'

January 12, 2026 4:01 AM EST Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $30.00 price target on Benitec BioPharma (NASDAQ: BNTC).The analyst comments "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login